Opus Genetics Launches Gene Therapy Trial for MERTK-related Retinitis Pigmentosa in Abu Dhabi

Opus Genetics has launched a clinical trial for a gene therapy to treat MERTK-related retinitis pigmentosa, a rare inherited eye disease affecting an estimated 60,000 patients worldwide. The trial is funded by Abu Dhabi's Healthcare Research and Innovation Fund and will commence at Cleveland Clinic Abu Dhabi in 2026. The gene therapy, OPGx-MERTK, is designed to deliver a functional copy of the MERTK gene to retinal cells, addressing the disease's cause of progressive vision loss and eventual blindness.